Navigation Links
Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
Date:11/8/2007

- Conference Call and Webcast on November 9 at 8:00 a.m. PST -

SAN DIEGO, Nov. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today reported financial results for the three and nine months ended September 30, 2007.

"Halozyme's unique capabilities in navigating the complexities of the extracellular matrix provide a number of exciting opportunities to build shareholder value," said Jonathan Lim, MD, Halozyme's President and CEO. "Building on our track record for accelerated development and commercialization and leveraging the franchises of our partners, we continue to pursue these opportunities by executing our Enable, Improve and Innovate programs. The Enable program focuses on making our partners' drugs better by potentially improving administration, extending product lifecycles, and increasing patients' compliance, and includes HYLENEX recombinant (hyaluronidase human injection) and our Enhanze(TM) Technology for drug delivery. In this regard, we are very pleased that we recently broadened our relationship with Baxter to apply our Enhanze Technology to their GAMMAGARD product. We are also excited about developing our own products through the Improve program, which focuses on co-formulations of rHuPH20 with marketed small molecules, particularly oncology and bisphosphonate drugs; and the Innovate program, which focuses on developing new molecular entities targeting the extracellular matrix with some exciting projects underway in oncology and dermatology."

Third Quarter 2007 Highlights

-- The completion of a new agreement with Baxter International Inc. to

a
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... 07, 2015 , ... CSM, a leading clinical trial supply company, today announced ... has an extensive background in financial management and accounting, bringing over 20 years of ... role, Morse will oversee all financial areas of the company to both strengthen CSM’s ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Pistoia ... to innovation in life science R&D, has attracted a number of new members ... top ten pharmaceutical company joining as a Core member, and DNAnexus and Tessella ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... Polytechnic Institute (WPI), offers new insights into how virulent fungi adapt through genetic ... spread, and how that battle leaves them temporarily weakened. These insights may provide ...
(Date:7/6/2015)...  Approximately 1% of the population inherits a common ... individuals are three times more likely to develop angina, ... the nation,s leading medical journals by researchers from the ... Photo - http://photos.prnewswire.com/prnh/20150706/230685 The ... (also known as "sixth disease") and occasional seizures in ...
Breaking Biology Technology:CSM Appoints Michael Morse as Vice President of Finance 2Pistoia Alliance Continues to Attract New Members 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3
... GENEVA , February 3 Viroblock SA, ... products, today,announced that Dr. Jamie Paterson will join Viroblock ... Paterson , a British national, can look back at 20 years ... Commercial Officer at Neurim Pharmaceuticals. During his 18 years at,Procter & ...
... This release is available in German . ... A white light appears out of nowhere. And a light ... upon close examination does the source of the apparently supernatural ... passes through thousands of infinitesimal lens structures measuring only a ...
... ... drug development community thanks to their complexity and substantial potential benefits for sponsors and patients. ... Inc. discusses the rapid evolution of the adaptive trial model and the latest thinking about ... ...
Cached Biology Technology:Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round 2Nano for the senses 2Nano for the senses 3Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 2Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 3Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 4
(Date:6/17/2015)... HILDEN, Germany , June 17, 2015 /PRNewswire/ ... Prime Standard: QIA) today launched new Investigator ® STR ... in the United States . The new ... multiple key genomic markers (short tandem repeats or STRs) for ... to evaluate the quality of DNA in each sample, a ...
(Date:6/17/2015)... PALM BEACH GARDENS, Fla. , June 17, ... identity management solutions, today announced that its U.are.U ... by Togo,s Eateries, Inc., ... based fast casual sandwich chain, to increase security, ... (POS). The Crossmatch fingerprint readers enable instant, non-repudiable identity ...
(Date:6/16/2015)... YORK , June 16, 2015  With the ... world, security remains a top concern. The recent compromise ... confirms the need for strong authentication within government agencies. ... Token, a biometric one-time password (OTP) authenticator, has been ... Standards (FIPS) 140-2 Level 3 validation for tamper proofing. ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... Jewish Health and four other research centers have been ... Heart Lung and Blood Institute as part of the ... national scientists to delve deeply into the biology of ... therapeutic options. The multi-center Lung Genomics Research Consortium will ...
... CITY, Calif., Oct. 7 DigitalPersona, Inc., a ... announced that Panasonic System Solutions Company is now ... field-upgradeable option on Panasonic,s modular point-of-sale (POS) workstation, ... a modular case that can be attached to ...
... degradation in dryland regions continuing to worsen, the ... scientist-recommended indicators for monitoring and assessing desertification that ... agreement was reached after two weeks of negotiations ... the Ninth Session of the Conference of the ...
Cached Biology News:NHLBI awards $11 million for molecular roadmap to chronic lung diseases 2Panasonic Offers U.are.U(R) Fingerprint Sensor From DigitalPersona on Stingray JS-950 Point-of-Sale Workstations 2Satellite data instrumental in combating desertification 2Satellite data instrumental in combating desertification 3
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
Request Info...
... new Thermo Electron RapidStak provides valuable walk-away ... a unique buffer nest technology for parallel ... RapidStak provides fast, reliable automation for any ... walk-away confidence. The RapidStak can be set-up ...
... genetically engineered endonuclease. This unique enzyme degrades ... having no proteolytic activity. It is effective ... possesses an exceptionally high specific activity. Ideal ... proteins, its use enables compliance with FDA ...
Biology Products: